Michael Wang

I am a Professor in The Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center. I obtained my M.D. from Shandong Medical University and M.S. from Beijing University, Medical School. I was a Fellow at the Fogarty National Center at NIH and trained in the lab for 6 years on cell biology and molecular biology. I completed my residency in the University of Michigan Hospitals and Yale-Norwalk Hospital. I received Fellowship training in Oncology and in Hematology at The University of Texas MD Anderson Cancer Center. I became a Faculty at MD Anderson in 2002.

I have published 200 peer-reviewed papers and have presented my work at national and international meetings. I am the founding and current Director of the Mantle Cell Lymphoma (MCL) Program of Excellence. I am also the founding and current Co-PI of the B cell Lymphoma Moon Shot Program. I served as the Co-Director of Clinical Trials at MD Anderson for 5 years. I am National PI of the multi-site international phase III registration trials in lymphoma.

In the clinic, I treat lymphoma with a special interest in mantle cell lymphoma, hosting the largest clinic for mantle cell lymphoma patients globally. In clinical research, I led 2 international clinical trials that has led to the FDA approvals for ibrutinib and acalabrutinib in mantle cell lymphoma.

In the lab, my interest are in multi-omics based new generation personalized trials, such as PDX models, new drug discovery and development, drug resistance, and novel targets. In translation research, I’m conducting clinical trial in lymphoma based on PDX models from my lab, called EXPLORE trial. Using genomics and robotic high-through put in vitro screening. I designed and am conducting a new generation of personalized clinical trial, by the name of MCL MATCH. I am the PI of a CPRIT grant and the PI for another 2 peer-reviewed NIH grants.